ABSTRACT:
Athlete’s foot, or tinea pedis, ranks among the dermatophytic infections clinicians encounter most often, settling characteristically in the toe-web clefts and along the soles. The usual culprits are keratin-digesting moulds—chiefly Trichophyton rubrum, with Trichophyton interdigitale and Epidermophyton floccosum contributing a smaller share. The condition seldom endangers life, yet the relentless itching, the tendency to return, and the doorway it opens to bacterial superinfection make it a genuine drain on day-to-day wellbeing. First-line agents—terbinafine together with azoles such as clotrimazole, miconazole, ketoconazole, and itraconazole—work well in principle, but in practice the drug struggles to reach the fungus through thick plantar skin, washes or rubs away before it can act, and is too often abandoned once the itching settles; rising resistance compounds the problem. Engineered carriers built at the nanometre scale—vesicles (liposomes, niosomes, transferosomes, ethosomes), emulsion-based systems (nanoemulsions, nanoemulgels), and solid carriers (polymeric and lipid nanoparticles)—are being developed to push more drug deeper, hold it there longer, and release it gradually, all while easing the dosing burden. The pages that follow trace the disease from its epidemiology and biology through diagnosis and standard care, then turn to these delivery innovations and the questions that still surround their clinical adoption.